Loading...

Microbix Biosystems

DB:2M4
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2M4
DB
CA$24M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Microbix Biosystems Inc., a life science company, manufactures viral and bacterial antigens and reagents for the diagnostics industry worldwide. The last earnings update was 70 days ago. More info.


Add to Portfolio Compare Print
2M4 Share Price and Events
7 Day Returns
0.7%
DB:2M4
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-11.2%
DB:2M4
-10.6%
DE Biotechs
-6.2%
DE Market
2M4 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Microbix Biosystems (2M4) 0.7% 5.6% -3.8% -11.2% -16.6% -32.6%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • 2M4 underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
2M4
Industry
5yr Volatility vs Market

2M4 Value

 Is Microbix Biosystems undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Microbix Biosystems. This is due to cash flow or dividend data being unavailable. The share price is €0.151.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Microbix Biosystems's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Microbix Biosystems's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2M4 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CAD CA$-0.09
TSX:MBX Share Price ** TSX (2019-04-23) in CAD CA$0.25
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Microbix Biosystems.

DB:2M4 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:MBX Share Price ÷ EPS (both in CAD)

= 0.25 ÷ -0.09

-2.78x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Microbix Biosystems is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Microbix Biosystems is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Microbix Biosystems's expected growth come at a high price?
Raw Data
DB:2M4 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.78x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Microbix Biosystems, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Microbix Biosystems's assets?
Raw Data
DB:2M4 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CAD CA$0.11
TSX:MBX Share Price * TSX (2019-04-23) in CAD CA$0.25
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:2M4 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:MBX Share Price ÷ Book Value per Share (both in CAD)

= 0.25 ÷ 0.11

2.36x

* Primary Listing of Microbix Biosystems.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Microbix Biosystems is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Microbix Biosystems's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Microbix Biosystems has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2M4 Future Performance

 How is Microbix Biosystems expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Microbix Biosystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Microbix Biosystems expected to grow at an attractive rate?
  • Unable to compare Microbix Biosystems's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Microbix Biosystems's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Microbix Biosystems's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:2M4 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2M4 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2M4 Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-12-31 12 1 -9
2018-09-30 13 -1 -9
2018-06-30 12 -1 -1
2018-03-31 11 -1 -1
2017-12-31 11 -1 -1
2017-09-30 10 0 -4
2017-06-30 11 1 -2
2017-03-31 10 1 -2
2016-12-31 10 1 -2
2016-09-30 10 1 1
2016-06-30 8 1 0
2016-03-31 8 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Microbix Biosystems is high growth as no earnings estimate data is available.
  • Unable to determine if Microbix Biosystems is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2M4 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Microbix Biosystems Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2M4 Past Financials Data
Date (Data in CAD Millions) EPS *
2018-12-31 -0.09
2018-09-30 -0.09
2018-06-30 -0.02
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.04
2017-06-30 -0.02
2017-03-31 -0.02
2016-12-31 -0.03
2016-09-30 0.01
2016-06-30 0.00
2016-03-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Microbix Biosystems will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Microbix Biosystems's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Microbix Biosystems's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Microbix Biosystems's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Microbix Biosystems's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Microbix Biosystems has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2M4 Past Performance

  How has Microbix Biosystems performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Microbix Biosystems's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Microbix Biosystems does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Microbix Biosystems's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Microbix Biosystems's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Microbix Biosystems's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Microbix Biosystems Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2M4 Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 12.09 -8.65 4.11 1.10
2018-09-30 12.51 -8.62 4.17 1.09
2018-06-30 11.93 -1.45 4.43 1.12
2018-03-31 11.47 -1.26 4.56 1.12
2017-12-31 11.12 -0.66 4.42 1.05
2017-09-30 10.19 -3.78 4.39 0.99
2017-06-30 10.84 -1.91 4.14 0.94
2017-03-31 10.32 -2.05 3.98 0.77
2016-12-31 10.41 -2.13 4.00 0.66
2016-09-30 9.52 0.75 3.65 0.49
2016-06-30 8.16 0.29 3.09 1.43
2016-03-31 8.13 0.32 3.14 1.21
2015-12-31 7.94 0.27 3.22 1.27
2015-09-30 8.87 0.61 3.47 1.28
2015-06-30 9.12 -0.14 3.50 0.62
2015-03-31 8.94 -0.01 3.03 0.79
2014-12-31 8.46 0.05 2.63 0.72
2014-09-30 8.40 0.17 2.50 0.69
2014-06-30 8.51 0.93 2.49 0.15
2014-03-31 8.38 0.69 2.54 0.29
2013-12-31 8.60 0.75 2.68 0.33
2013-09-30 7.57 0.00 2.68 0.45
2013-06-30 6.99 -0.71 2.78 0.72
2013-03-31 6.50 -1.64 3.22 0.64
2012-12-31 6.10 -2.50 3.69 0.68
2012-09-30 6.67 -2.39 3.77 0.66
2012-06-30 6.92 -2.55 3.84 0.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Microbix Biosystems has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Microbix Biosystems has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Microbix Biosystems improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Microbix Biosystems's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Microbix Biosystems has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2M4 Health

 How is Microbix Biosystems's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Microbix Biosystems's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Microbix Biosystems is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Microbix Biosystems's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Microbix Biosystems's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Microbix Biosystems Company Filings, last reported 3 months ago.

DB:2M4 Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 10.27 6.54 0.28
2018-09-30 10.35 6.26 0.04
2018-06-30 18.48 6.44 0.06
2018-03-31 18.31 6.20 0.09
2017-12-31 18.44 6.31 0.05
2017-09-30 15.17 7.28 0.05
2017-06-30 15.86 6.89 0.16
2017-03-31 15.59 6.98 0.03
2016-12-31 15.28 6.73 0.00
2016-09-30 15.29 7.37 0.01
2016-06-30 14.34 7.44 0.01
2016-03-31 14.21 7.44 0.01
2015-12-31 13.96 7.34 0.07
2015-09-30 13.68 7.19 0.10
2015-06-30 13.12 6.62
2015-03-31 12.89 6.53 1.12
2014-12-31 10.61 6.51 0.79
2014-09-30 9.84 5.92 0.55
2014-06-30 7.82 6.24 0.45
2014-03-31 7.09 6.20 1.15
2013-12-31 5.84 5.36 0.21
2013-09-30 5.72 5.23 0.26
2013-06-30 3.90 7.00 0.05
2013-03-31 4.00 7.04 0.12
2012-12-31 3.81 6.73 0.17
2012-09-30 5.24 5.80 0.23
2012-06-30 5.04 6.02 0.56
  • Microbix Biosystems's level of debt (63.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (91.8% vs 63.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Microbix Biosystems has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Microbix Biosystems has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -23.5% per year.
X
Financial health checks
We assess Microbix Biosystems's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Microbix Biosystems has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2M4 Dividends

 What is Microbix Biosystems's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Microbix Biosystems dividends.
If you bought €2,000 of Microbix Biosystems shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Microbix Biosystems's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Microbix Biosystems's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2M4 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Microbix Biosystems has not reported any payouts.
  • Unable to verify if Microbix Biosystems's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Microbix Biosystems's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Microbix Biosystems has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Microbix Biosystems's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Microbix Biosystems afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Microbix Biosystems has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2M4 Management

 What is the CEO of Microbix Biosystems's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Cameron Groome
COMPENSATION CA$305,614
TENURE AS CEO 1.8 years
CEO Bio

Mr. Cameron Groome has been the Chief Executive Officer and President of Microbix Biosystems Inc. since July 24, 2017. Mr. Groome served as the Chief Executive Officer and President of Avivagen, Inc. since March 11, 2013 until February 9, 2017. Mr. Groome served as Executive Vice-President of Corporate & Strategic Development at Bioniche Life Sciences Inc. (now known as Telesta Therapeutics Inc.) since June 27, 2006. He has more than 20 years of experience as an Equity Analyst, Industry Commentator, Investment Banker and Corporate Advisor and Industry Commentator in the Canadian life sciences industry. Mr. Groome joined Bioniche in June 2006 from a major Canadian investment dealer, where he led its life sciences investment banking activities. He is a life sciences business and finance leader. He served as Director of Investment Banking for Blackmont Capital, as Managing Director, Corporate and Investment Banking for National Bank Financial. He served as an External Advisor to the Board of Directors of Trillium Therapeutics. He served as an Equity Analyst of National Bank Financial, Inc., Research Division and Crédit Suisse AG, Research Division and as an Analyst at First Marathon Securities, Ltd., Research Division and Gleacher & Company, Inc., Research Division. He serves as Director of ScarX Therapeutics Inc. He has been an Independent Director of Microbix Biosystems Inc. since March 8, 2012. He served as a Director of Avivagen Inc. since April 24, 2013 until February 9, 2017. He is a member of the Life Sciences Advisory Board for Canada’s Department of Foreign Affairs and International Trade. Mr. Groome holds a Bachelor of Commerce, Finance and Marketing from Concordia University (Montréal, Québec).

CEO Compensation
  • Cameron's compensation has been consistent with company performance over the past year.
  • Cameron's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Microbix Biosystems management team in years:

4.4
Average Tenure
  • The tenure for the Microbix Biosystems management team is about average.
Management Team

Bill Gastle

TITLE
Founder & Executive Chairman
COMPENSATION
CA$202K

Cameron Groome

TITLE
President
COMPENSATION
CA$306K
TENURE
1.8 yrs

Jim Currie

TITLE
Chief Financial Officer
COMPENSATION
CA$193K
TENURE
2.4 yrs

Phil Casselli

TITLE
Senior Vice President of Sales
COMPENSATION
CA$187K
TENURE
6.4 yrs

Vaughn Embro-Pantalony

TITLE
Executive Director

Mark Luscher

TITLE
Senior Vice President of Scientific Affairs
TENURE
11.4 yrs

Christopher Lobb

TITLE
Compliance Officer
Board of Directors Tenure

Average tenure of the Microbix Biosystems board of directors in years:

12.2
Average Tenure
  • The average tenure for the Microbix Biosystems board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Bill Gastle

TITLE
Founder & Executive Chairman
COMPENSATION
CA$202K
TENURE
6.4 yrs

Cameron Groome

TITLE
President
COMPENSATION
CA$306K
TENURE
7.1 yrs

Vaughn Embro-Pantalony

TITLE
Executive Director
TENURE
12.2 yrs

Martin Marino

TITLE
Independent Director
TENURE
10.2 yrs

Mark Cochran

TITLE
Independent Director
TENURE
16.5 yrs

Joe Renner

TITLE
Independent Director
TENURE
16.2 yrs

Peter Blecher

TITLE
Independent Director
TENURE
13.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Microbix Biosystems insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
05. Mar 19 Buy Cameron Groome Individual 04. Mar 19 04. Mar 19 103,333 €0.17 €17,120
17. Jan 19 Buy Mark Luscher Individual 15. Jan 19 15. Jan 19 11,000 €0.17 €1,818
30. Aug 18 Buy Cameron Groome Individual 29. Aug 18 29. Aug 18 100,000 €0.17 €17,166
21. Aug 18 Buy William Gastle Individual 20. Aug 18 20. Aug 18 5,000 €0.17 €870
X
Management checks
We assess Microbix Biosystems's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Microbix Biosystems has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2M4 News

Simply Wall St News

2M4 Company Info

Description

Microbix Biosystems Inc., a life science company, manufactures viral and bacterial antigens and reagents for the diagnostics industry worldwide. The company produces infectious disease antigens, including viral, bacterial, and parasitic products, which are used in various applications, such as immunodiagnostic assays comprising ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry; controls for diagnostic assays. Its infectious disease antigens also used in controls for diagnostic assays, basic and applied research in virology, microbiology, cell biology, immunology, and pathology, or for vaccine and antiviral research and development. The company also provides quality assessment products, including PROCEEDx Verification/Validation samples, which are research use only products for use in test system IQ/OQ/PQ, verification/validation, and training; PTDx proficiency testing products; and REDx Controls, which are designed to enhance the diagnostic quality outcome by early detection of the deviations from desired assay performance. In addition, it develops Kinlytic Urokinase for injection, a thrombolytic biologic drug used to treat blood clots; and LumiSort cell-sorting, a technology for sorting of particles that could be used to enrich cell populations of interest, such as in sexing semen. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.

Details
Name: Microbix Biosystems Inc.
2M4
Exchange: DB
Founded: 1988
CA$16,119,729
96,972,705
Website: http://microbix.com
Address: Microbix Biosystems Inc.
265 Watline Avenue,
Mississauga,
Ontario, L4Z 1P3,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX MBX Common Shares The Toronto Stock Exchange CA CAD 01. Oct 1992
OTCPK MBXB.F Common Shares Pink Sheets LLC US USD 01. Oct 1992
DB 2M4 Common Shares Deutsche Boerse AG DE EUR 01. Oct 1992
Number of employees
Current staff
Staff numbers
0
Microbix Biosystems employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 21:54
End of day share price update: 2019/04/23 00:00
Last earnings filing: 2019/02/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.